Taizhou Hanzhong biomedical co. LTD
Quick facts
Phase 3 pipeline
- HX008 · Oncology
HX008 is a monoclonal antibody that blocks PD-L1, preventing its interaction with PD-1 and PD-L2 to enhance anti-tumor immune responses. - HX008 + TACE · Oncology
HX008 is a PD-1 inhibitor combined with TACE (transarterial chemoembolization) to enhance anti-tumor immunity while delivering localized chemotherapy to hepatic tumors. - Temozolomide + TACE · Oncology
Temozolomide is an alkylating agent that works by interfering with DNA replication in cancer cells, while TACE is a minimally invasive procedure that involves the insertion of a catheter to deliver chemotherapy directly to the tumor.
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
- Taizhou Hanzhong biomedical co. LTD portfolio CI brief
- Taizhou Hanzhong biomedical co. LTD pipeline updates RSS
Frequently asked questions about Taizhou Hanzhong biomedical co. LTD
What is Taizhou Hanzhong biomedical co. LTD's pipeline?
Taizhou Hanzhong biomedical co. LTD has 3 drugs in Phase 3, 0 in Phase 2, 0 in Phase 1. Late-stage candidates include HX008, HX008 + TACE, Temozolomide + TACE.
Related
- Sector hub: All tracked pharma companies